You are here: Industry Insights > msd

News List

US FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy Pharmaceutical-Business-Review
December 02, 2021
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) to treat BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer patients.
Leslie A. Brun Resigns from Merck Board of Directors firstwordpharma
August 23, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Leslie A. Brun, its independent lead director, has resigned from its Board of Directors, effective August 19, 2021.
MSD, Bayer’s heart failure med Verquvo gains EU approval pharmatimes
July 23, 2021
The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction.
MSD’s Keytruda scores EU approval in certain oesophageal cancer patients pharmatimes
July 02, 2021
MSD’s immunotherapy Keytruda has received approval from the European Commission (EC) in combination with chemotherapy as a first line treatment for certain oesophageal cancer patients.
Koselugo Approved in EU for Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas americanpharmaceuticalreview
June 23, 2021
AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) ...
Lynparza shows promise in preventing cancer recurrence pharmatimes
June 04, 2021
AstraZeneca and MSD's Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma prnasia
June 03, 2021
QBiotics Group Limited, a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology ...
MSD signs voluntary licensing agreements with five Indian pharma firms for Molnupiravir expresspharma
April 28, 2021
The agreements have been signed with Cipla, Dr Reddy’s Laboratories, Emcure Pharmaceuticals, Hetero Labs and Sun Pharmaceutical Industries.
NHS England makes Keytruda available for advanced colorectal cancer during pandemic pharmatimes
March 29, 2021
NHS England has reached an interim treatment agreement with MSD for Keytruda for the treatment of certain advanced colorectal cancer patients during the COVID-19 pandemic.
IDMC Concluded Lynparza Trial Crossed Superiority Boundary for Invasive Disease-Free Survival americanpharmaceuticalreview
February 20, 2021
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page